<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOPRESSOR HCT- metoprolol tartrate and hydrochlorothiazide tablet </strong><br>Validus Pharmaceuticals LLC<br></p></div>
<h1>
<span class="Bold">Lopressor HCT<span class="Sup">®</span></span><br><span class="Bold">metoprolol tartrate USP and hydrochlorothiazide USP</span><br><br><span class="Bold">50/25 Tablets</span><br><span class="Bold">100/25 Tablets</span><br><span class="Bold">100/50 Tablets</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-1"></a><p></p>
<p class="First">Beta Blocker/Diuretic Antihypertensive</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Prescribing Information</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-2"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">Lopressor HCT has the antihypertensive effect of Lopressor®, metoprolol tartrate, a selective beta1-adrenoreceptor blocking agent, and the antihypertensive and diuretic actions of hydrochlorothiazide. It is available as tablets for oral administration. The 50/25 tablets contain 50 mg of metoprolol tartrate USP and 25 mg of hydrochlorothiazide USP; the 100/25 tablets contain 100 mg of metoprolol tartrate USP and 25 mg of hydrochlorothiazide USP; and the 100/50 tablets contain 100 mg of metoprolol tartrate USP and 50 mg of hydrochlorothiazide USP. Metoprolol tartrate USP is (±)-1-(Isopropylamino)-3-[<span class="Italics">p</span>-(2-methoxyethyl)phenoxy]-2-propanol L-(+)-tartrate (2:1) salt, and its structural formula is</p>
<div class="Figure"><img alt="
lopressor-hct-01
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8964894-3cd8-41c1-a844-148d2ef38a88&amp;name=lopressor-hct-01.jpg"></div>
<p>Metoprolol tartrate USP is a white, crystalline powder. It is very soluble in water; freely soluble in methylene chloride, in chloroform, and in alcohol; slightly soluble in acetone; and insoluble in ether. Its molecular weight is 684.82.</p>
<p>Hydrochlorothiazide is 6-chloro-3, 4-dihydro-2 <span class="Italics">H</span>-1,2,4-benzothiadiazine-7- sulfonamide 1,1-dioxide, and its structural formula is</p>
<div class="Figure"><img alt="
lopressor-hct-02
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8964894-3cd8-41c1-a844-148d2ef38a88&amp;name=lopressor-hct-02.jpg"></div>
<p>Hydrochlorothiazide USP is a white, or practically white, practically odorless, crystalline powder. It is freely soluble in sodium hydroxide solution, in <span class="Italics">n</span>-butylamine, and in dimethylformamide; sparingly soluble in methanol; slightly soluble in water; and insoluble in ether, in chloroform, and in dilute mineral acids. Its molecular weight is 297.73.</p>
<p><span class="Italics">Inactive Ingredients:</span> Cellulose compounds, colloidal silicon dioxide, D&amp;C Yellow No. 10 (100/50-mg tablets), FD&amp;C Blue No. 1 (50/25-mg tablets), FD&amp;C Red No. 40 and FD&amp;C Yellow No. 6 (100/25-mg tablets), lactose, magnesium stearate, povidone, sodium starch glycolate, corn starch, stearic acid, and sucrose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-3"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection2"></a><a name="section-3.1"></a><p></p>
<p class="First">Lopressor</p>
<p>Lopressor is a beta-adrenergic receptor blocking agent. In vitro and in vivo animal studies have shown that it has a preferential effect on beta<span class="Sub">1</span> adrenoreceptors, chiefly located in cardiac muscle. This preferential effect is not absolute, however, and at higher doses, Lopressor also inhibits beta2 adrenoreceptors, chiefly located in the bronchial and vascular musculature.</p>
<p>Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and (4) reduction of reflex orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
<p>Relative beta<span class="Sub">1</span> selectivity has been confirmed by the following: (1) In normal subjects, Lopressor is unable to reverse the beta<span class="Sub">2</span>-mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective (beta<span class="Sub">1</span> plus beta<span class="Sub">2</span>) beta blockers, which completely reverse the vasodilating effects of epinephrine. (2) In <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients, Lopressor reduces FEV<span class="Sub">1</span> and FVC significantly less than a nonselective beta blocker, propranolol at equivalent beta<span class="Sub">1</span>-receptor blocking doses.</p>
<p>Lopressor has no intrinsic sympathomimetic activity and only weak membrane-stabilizing activity. Lopressor crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration. Animal and human experiments indicate that Lopressor slows the sinus rate and decreases AV nodal conduction.</p>
<p>In controlled clinical studies, Lopressor has been shown to be an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics, at dosages of 100-450 mg daily. In controlled, comparative, clinical studies, Lopressor has been shown to be as effective an antihypertensive agent as propranolol, methyldopa, and thiazide-type diuretics, and to be equally effective in supine and standing positions.</p>
<p>The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of renin activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection3"></a><a name="section-3.2"></a><p></p>
<p class="First">Pharmacokinetics</p>
<p>In man, absorption of Lopressor is rapid and complete. Plasma levels following oral administration, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism.</p>
<p>Plasma levels achieved are highly variable after oral administration. Only a small fraction of the drug (about 12%) is bound to human serum albumin. Metoprolol is a racemic mixture of R- and S-enantiomers. Less than 5% of an oral dose of Lopressor is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no clinical significance. The systemic availability and half-life of Lopressor in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> do not differ to a clinically significant degree from those in normal subjects. Consequently, no reduction in dosage is usually needed in patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.</p>
<p>In elderly subjects with clinically normal renal function, there are no significant differences in Lopressor pharmacokinetics compared to young subjects.</p>
<p>Lopressor is extensively metabolized by the cytochrome P450 enzyme system in the liver. The oxidative metabolism of Lopressor is under genetic control with a major contribution of the polymorphic cytochrome P450 isoform 2D6 (CYP2D6). There are marked ethnic differences in the prevalence of the poor metabolizers (PM) phenotype. Approximately 7% of Caucasians and less than 1% Asian are poor metabolizers.</p>
<p>Poor CYP2D6 metabolizers exhibit several-fold higher plasma concentrations of Lopressor than extensive metabolizers with normal CYP2D6 activity. The elimination half-life of metoprolol is about 7.5 hours in poor metabolizers and 2.8 hours in extensive metabolizers. However, the CYP2D6 dependent metabolism of Lopressor seems to have little or no effect on safety or tolerability of the drug. None of the metabolites of Lopressor contribute significantly to its beta-blocking effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection4"></a><a name="section-3.3"></a><p></p>
<p class="First">Pharmacodynamics</p>
<p>Significant beta-blocking effect (as measured by reduction of exercise heart rate) occurs within 1 hour after oral administration, and its duration is dose-related. For example, a 50% reduction of the maximum registered effect after single oral doses of 20, 50, and 100 mg occurred at 3.3, 5.0, and 6.4 hours, respectively, in normal subjects. After repeated oral dosages of 100 mg twice daily, a significant reduction in exercise systolic blood pressure was evident at 12 hours.</p>
<p>There is a linear relationship between the log of plasma levels and reduction of exercise heart rate. However, antihypertensive activity does not appear to be related to plasma levels. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to dose, selection of proper dosage requires individual titration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection5"></a><a name="section-3.4"></a><p></p>
<p class="First">Hydrochlorothiazide</p>
<p>Thiazides affect the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage, all thiazides are approximately equal in their diuretic potency. Thiazides increase excretion of sodium and chloride in approximately equivalent amounts. Natriuresis causes a secondary loss of potassium.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not affect normal blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection6"></a><a name="section-3.5"></a><p></p>
<p class="First">Pharmacokinetics</p>
<p>Hydrochlorothiazide is rapidly absorbed, as indicated by peak plasma concentrations 1-2.5 hours after oral administration. Plasma levels of the drug are proportional to dose; the concentration in whole blood is 1.6-1.8 times higher than in plasma. Thiazides are eliminated rapidly by the kidney. After oral administration of 25- to 100-mg doses, 72-97% of the dose is excreted in the urine, indicating dose-independent absorption. Hydrochlorothiazide is eliminated from plasma in a biphasic fashion with a terminal half-life of 10-17 hours. Plasma protein binding is 67.9%. Plasma clearance is 15.9-30.0 L/hr; volume of distribution is 3.6-7.8 L/kg.</p>
<p>Gastrointestinal absorption of hydrochlorothiazide is enhanced when administered with food. Absorption is decreased in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and the pharmacokinetics are considerably different in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection7"></a><a name="section-3.6"></a><p></p>
<p class="First">Pharmacodynamics</p>
<p>The onset of action of thiazides occurs in 2 hours and the peak effect at about 4 hours. The action persists for approximately 6-12 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-4"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">Lopressor HCT is indicated for the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p><span class="Bold">This fixed-combination drug is not indicated for initial therapy of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. If the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components.</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-5"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection8"></a><a name="section-5.1"></a><p></p>
<p class="First">Lopressor</p>
<p>Lopressor is contraindicated in <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> greater than first degree, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, and overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <a href="#splSectionWarnings">WARNINGS</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Lopressor and related derivatives, or to any of the excipients; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other beta blockers (cross sensitivity between beta blockers can occur).</p>
<p>Sick-sinus syndrome.</p>
<p>Severe peripheral arterial circulatory disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection9"></a><a name="section-5.2"></a><p></p>
<p class="First">Hydrochlorothiazide</p>
<p>Hydrochlorothiazide is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this or other sulfonamide-derived drugs (see <a href="#splSectionWarnings">WARNINGS</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-6"></a><p></p>
<h1>
WARNINGS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection10"></a><a name="section-6.1"></a><p></p>
<p class="First">Lopressor</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>:</span> Sympathetic stimulation is a vital component supporting circulatory function in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive patients who have <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> controlled by digitalis and diuretics, Lopressor should be administered cautiously.</p>
<p><span class="Bold Italics">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>:</span> Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of impending <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continues, despite adequate digitalization and diuretic therapy, Lopressor should be withdrawn.</p>
<table width="100%">
<caption><span></span></caption>
<col align="left" width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule" align="left">
<span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic Heart Disease</span>:</span> Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> have been reported. Even in the absence of overt <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, when discontinuing therapy, Lopressor should not be withdrawn abruptly, and patients should be cautioned against interruption of therapy without the physician's advice (see <a href="#splSectionPrecautionsPatientInfo">PRECAUTIONS, Information for Patients</a>).
</td></tr></tbody>
</table>
<p><span class="Bold"><span class="Italics">Bronchospastic Diseases:</span> PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA BLOCKERS, including Lopressor HCT. Because of its relative beta<span class="Sub">1</span> selectivity, however, Lopressor may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Since beta<span class="Sub">1</span> selectivity is not absolute, a beta<span class="Sub">2</span>-stimulating agent should be administered concomitantly, and the lowest possible dose of Lopressor should be used. In these circumstances it would be prudent initially to administer Lopressor in smaller doses three times daily, instead of larger doses two times daily, to avoid the higher plasma levels associated with the longer dosing interval (see <a href="#splSectionDosageAdministration">DOSAGE AND ADMINISTRATION</a>).</span></p>
<p><span class="Bold Italics">Major Surgery:</span> Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span> Lopressor should be used with caution in diabetic patients if a beta-blocking agent is required. Beta blockers, including Lopressor HCT, may mask <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> occurring with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, but other manifestations such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> may not be significantly affected. Selective beta blockers do not potentiate insulin-induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and, unlike nonselective beta blockers, do not delay recovery of blood glucose to normal levels.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>:</span> If Lopressor is used in the setting of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated.  Administration of beta blockers alone in the setting of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> in skeletal muscle.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>:</span> Beta-adrenergic blockade may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta blockade, which might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection11"></a><a name="section-6.2"></a><p></p>
<p class="First">Hydrochlorothiazide</p>
<p>Thiazides should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Thiazides may add to or potentiate the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.</p>
<p>Sensitivity reactions are more likely to occur in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>The possibility of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-7"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-7.1"></a><p></p>
<p class="First">General</p>
<p><span class="Bold Italics">Lopressor:</span> Lopressor should be used with caution in patients with impaired hepatic function.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, namely <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (see <a href="#splSectionPrecautionsLabInfo">Laboratory Tests</a> and <a href="#splSectionPrecautionsDrugInteract">Drug/Drug Interactions</a>). Warning signs are dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbance</span>, such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially in cases of brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or severe cirrhosis.</p>
<p>Interference with adequate oral intake of electrolytes will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may be avoided or treated by the use of potassium supplements or foods with high potassium content.</p>
<p>Any chloride deficit is generally mild and usually does not require specific treatment, except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In cases of actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">Latent diabetes</span> may become manifest during thiazide administration (see <a href="#splSectionPrecautionsDrugInteract">Drug/Drug Interactions</a>).</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, withholding or discontinuing diuretic therapy should be considered.</p>
<p>Calcium excretion is decreased by thiazides. Pathological changes in the parathyroid gland with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. The common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>, such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span>, have not been seen.</p>
<p>Thiazide diuretics have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-7.2"></a><p></p>
<p class="First">Information for Patients</p>
<p>Patients should be advised to take Lopressor HCT regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next scheduled dose (without doubling it). Patients should not discontinue Lopressor HCT without consulting the physician.</p>
<p>Patients should be advised (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with Lopressor HCT has been determined; (2) to contact the physician if any difficulty in breathing occurs; (3) to inform the physician or dentist before any type of surgery that he or she is taking Lopressor HCT.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="splSectionPrecautionsLabInfo"></a><a name="section-7.3"></a><p></p>
<p class="First">Laboratory Tests</p>
<p><span class="Bold Italics">Lopressor:</span> Clinical laboratory findings may include elevated levels of serum transaminase, alkaline phosphatase, and lactate dehydrogenase.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> Initial and periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-7.4"></a><p></p>
<p class="First">Drug/Drug Interactions</p>
<p><span class="Bold Italics">Lopressor:</span> Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with Lopressor plus a catecholamine depletor should therefore be closely observed for evidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may produce <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p>Both digitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Bold Italics">Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span>:</span> While taking beta blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection12"></a><a name="section-7.5"></a><p></p>
<p class="First">General Anesthetics</p>
<p>Some inhalation anesthetics may enhance the cardiodepressant effect of beta blockers (see <a href="#splSection10">WARNINGS; Lopressor; Major Surgery</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection13"></a><a name="section-7.6"></a><p></p>
<p class="First">CYP2D6 Inhibitors</p>
<p>Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of Lopressor. Strong inhibition of CYP2D6 would mimic the pharmacokinetics of CYP2D6 poor metabolizer. Caution should therefore be exercised when administering potent CYP2D6 inhibitors with Lopressor. Known clinically significant potent inhibitors of CYP2D6 are antidepressants such as fluoxetine, paroxetine or bupropion, antipsychotics such as thioridazine, antiarrhythmics such as quinidine or propafenone, antiretrovirals such as ritonavir, antihistamines such as diphenhydramine, antimalarials such as hydroxychloroquine or quinidine, antifungals such as terbinafine and medications for <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span> such as cimetidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection14"></a><a name="section-7.7"></a><p></p>
<p class="First">Clonidine</p>
<p>If a patient is treated with clonidine and Lopressor concurrently, and clonidine treatment is to be discontinued, Lopressor should be stopped several days before clonidine is withdrawn. <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">Rebound hypertension</span> that can follow withdrawal of clonidine may be increased in patients receiving concurrent beta blocker treatment.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop during concomitant use of steroids or ACTH.</p>
<p>Insulin requirements in diabetic patients may be increased, decreased, or unchanged.</p>
<p>Thiazides may decrease arterial responsiveness to norepinephrine, but not enough to preclude effectiveness of the pressor agent for therapeutic use.</p>
<p>Thiazides may increase the responsiveness to tubocurarine.</p>
<p>Lithium renal clearance is reduced by thiazides, increasing the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
<p>There have been rare reports in the literature of <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> occurring with the concomitant use of hydrochlorothiazide and methyldopa.</p>
<p>Concurrent administration of some nonsteroidal anti-inflammatory agents may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics.</p>
<p><span class="Bold Italics">Cholestyramine and colestipol resins:</span> Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="splSectionPrecautionsDrugLab"></a><a name="section-7.8"></a><p></p>
<p class="First">Drug/Laboratory Test Interactions</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> Thiazides may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. Thiazides should be discontinued before tests for parathyroid function are made. (see <a href="#splSectionPrecautionsGeneral">General,</a><span class="Italics"> <a href="#splSectionPrecautionsGeneral">Hydrochlorothiazide,</a> </span><a href="#splSectionPrecautionsGeneral">Calcium excretion</a>).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-7.9"></a><p></p>
<p class="First">Carcinogenesis, Mutagenesis, Impairment of Fertility</p>
<p><span class="Bold Italics">Lopressor HCT:</span> Carcinogenicity and mutagenicity studies have not been conducted with Lopressor HCT. Lopressor HCT produced no evidence of impaired fertility in male or female rats administered gavaged doses up to 200/50 mg/kg (100/50 times the maximum recommended daily human dose) prior to mating and throughout gestation and rearing of young.</p>
<p><span class="Bold Italics">Lopressor:</span> Long-term studies in animals have been conducted to evaluate carcinogenic potential. In a 2-year study in rats at three oral dosage levels of up to 800 mg/kg per day, there was no increase in the development of spontaneously occurring benign or malignant neoplasms of any type. The only histologic changes that appeared to be drug related were an increased incidence of generally mild focal accumulation of foamy macrophages in pulmonary alveoli and a slight increase in biliary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. In a 21-month study in Swiss albino mice at three oral dosage levels of up to 750 mg/kg per day, benign lung tumors (small <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>) occurred more frequently in female mice receiving the highest dose than in untreated control animals. There was no increase in malignant or total (benign plus malignant) lung tumors, or in the overall incidence of tumors or <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. This 21-month study was repeated in CD-1 mice, and no statistically or biologically significant differences were observed between treated and control mice of either sex for any type of tumor.</p>
<p>All mutagenicity tests performed (a dominant lethal study in mice, chromosome studies in somatic cells, a <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>/</span>mammalian-microsome mutagenicity test, and a nucleus anomaly test in somatic interphase nuclei) were negative.</p>
<p>No evidence of impaired fertility due to Lopressor was observed in a study performed in rats at doses up to 55.5 times the maximum daily human dose of 450 mg.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses up to approximately 600 mg/kg/day) or in male and female rats (at doses up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic in in vitro assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (Ames assay) and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in in vivo assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the <span class="Italics">Drosophila</span> sex-linked recessive lethal trait gene. Positive test results were obtained only in the in vitro CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 μg/mL, and in the <span class="Italics">Aspergillus nidulans</span> nondisjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg/day, respectively, prior to mating and throughout gestation.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-7.10"></a><p></p>
<p class="First">Pregnancy: Teratogenic Effects. Pregnancy Category C</p>
<p><span class="Bold Italics">Lopressor HCT:</span> No evidence of adverse effects on pregnancy or the fetus were observed in rats when dams were administered gavaged doses up to 200/50 mg/kg of Lopressor HCT (100/50 times the maximum recommended daily human dose) during the period of organogenesis. Increased postimplantation loss and decreased postnatal survival were observed with these doses when administered later in pregnancy (gestation days 15-21). In rabbits, increased fetal loss was observed with oral doses of 25/6.25 mg/kg of Lopressor HCT (12/6 times the maximum recommended daily human dose), but not with lower doses. There are no adequate and well-controlled studies of Lopressor HCT in pregnant women. Lopressor HCT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold Italics">Lopressor:</span> Lopressor has been shown to increase postimplantation loss and decrease neonatal survival in rats at doses up to 55.5 times the maximum daily human dose of 450 mg. Distribution studies in mice confirm exposure of the fetus when Lopressor is administered to the pregnant animal. These studies have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> Studies in which hydrochlorothiazide was orally administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg/kg/day, respectively, provided no evidence of harm to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="splSectionPrecautionsPregnancyNonTerat"></a><a name="section-7.11"></a><p></p>
<p class="First">Nonteratogenic Effects</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> Thiazides cross the placental barrier and appear in cord blood, and there is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-7.12"></a><p></p>
<p class="First">Nursing Mothers</p>
<p>Lopressor is excreted in breast milk in a very small quantity. An infant consuming 1 liter of breast milk daily would receive a dose of metoprolol of less than 1 mg. Thiazides are also excreted in breast milk. If the use of Lopressor HCT is deemed essential, the patient should stop nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-7.13"></a><p></p>
<p class="First">Pediatric Use</p>
<p>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-7.14"></a><p></p>
<p class="First">Geriatric Use</p>
<p>Clinical studies of Lopressor HCT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Hydrochlorothiazide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#splSectionWarnings">WARNINGS</a>). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-8"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection15"></a><a name="section-8.1"></a><p></p>
<p class="First">Lopressor HCT</p>
<p>The following adverse reactions were reported in controlled clinical studies of the combination of Lopressor and hydrochlorothiazide.</p>
<p><span class="Bold Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> or <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span> have each been reported in about 10 in 100 patients.</p>
<p><span class="Bold Italics">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have each occurred in about 10 in 100 patients. <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmare</span> has occurred in 1 in 100 patients.</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> has occurred in about 6 in 100 patients. Decreased exercise tolerance and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> have each occurred in about 1 of 100 patients.</p>
<p><span class="Bold Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, digestive disorder, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> have each occurred in about 1 in 100 patients.</p>
<p><span class="Bold Italics">Metabolic and Nutritional:</span> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> has occurred in fewer than 10 in 100 patients. <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> have each occurred in 1 in 100 patients.</p>
<p><span class="Bold Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, and <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span> have each been reported in 1 in 100 patients.</p>
<p><span class="Bold Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span> and <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> have each occurred in 1 in 100 patients.</p>
<p><span class="Bold Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> has occurred in 1 in 100 patients.</p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span> has occurred in 1 in 100 patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection16"></a><a name="section-8.2"></a><p></p>
<p class="First">Lopressor</p>
<p>Most adverse effects have been mild and transient.</p>
<p><span class="Bold Italics">Central Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Tiredness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have occurred in about 10 of 100 patients. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> has been reported in about 5 of 100 patients. <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Mental confusion</span> and short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span> have been reported. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> have also been reported, but a drug relationship is not clear.</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> have occurred in approximately 3 of 100 patients. <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Cold extremities</span>; <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, usually of the Raynaud type; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have been reported. <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">Gangrene</span> in patients with pre-existing severe peripheral circulatory disorders has also been reported very rarely (see <a href="#splSectionContraindications">CONTRAINDICATIONS</a>, <a href="#splSectionWarnings">WARNINGS</a>, and <a href="#splSectionPrecautions">PRECAUTIONS</a>).</p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheezing</span> (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>) has been reported in fewer than 1 of 100 patients (see <a href="#splSectionWarnings">WARNINGS</a>). <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> has also been reported.</p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> has occurred in about 5 of 100 patients. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">gastric pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> have been reported in 1 of 100, or fewer, patients. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> was a common occurrence. Postmarketing experience reveals very rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and non-specific hepatic dysfunction. Isolated cases of transaminase, alkaline phosphatase, and lactic dehydrogenase elevations have also been reported.</p>
<p><span class="Bold Italics">Hypersensitive Reactions:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> has occurred in fewer than 1 of 100 patients. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> has been reported. Very rarely, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and worsening of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> has been reported.</p>
<p><span class="Bold Italics">Miscellaneous:</span> Peyronie's disease has been reported in fewer than 1 of 100,000 patients. <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> has been reported. There have been very rare reports of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> (relationship to Lopressor has not been definitely established).</p>
<p>The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta blocker practolol has not been reported with Lopressor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection17"></a><a name="section-8.3"></a><p></p>
<p class="First">Potential Adverse Reactions</p>
<p>A variety of adverse reactions not listed above have been reported with other beta-adrenergic blocking agents and should be considered potential adverse reactions to Lopressor.</p>
<p><span class="Bold Italics">Central Nervous System:</span> Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics.</p>
<p><span class="Bold Italics">Cardiovascular:</span> Intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (see <a href="#splSectionContraindications">CONTRAINDICATIONS</a>).</p>
<p><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>.</p>
<p><span class="Bold Italics">Hypersensitive Reactions:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection18"></a><a name="section-8.4"></a><p></p>
<p class="First">Postmarketing Experience</p>
<p>The following adverse reactions have been reported during postapproval use of Lopressor: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, an increase in blood triglycerides and a decrease in High Density Lipoprotein (HDL). Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection19"></a><a name="section-8.5"></a><p></p>
<p class="First">Hydrochlorothiazide</p>
<p>The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency. Consequently the reactions are categorized by organ systems and are listed in decreasing order of severity and not frequency.</p>
<p><span class="Bold Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic cholestatic), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, cramping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> (may be potentiated by alcohol, barbiturates, or narcotics).</p>
<p><span class="Bold Italics">Neurologic:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>.</p>
<p><span class="Bold Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.</p>
<p><span class="Bold Italics">Hypersensitive Reactions:</span> Necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-9"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection20"></a><a name="section-9.1"></a><p></p>
<p class="First">Acute Toxicity</p>
<p>Several cases of overdosage with Lopressor have been reported, some leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported with hydrochlorothiazide.</p>
<p>Oral LD <span class="Sub">50</span>'s (mg/kg): mice, 1158 (Lopressor); rats, 3090 (Lopressor), 2750 (hydrochlorothiazide).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection21"></a><a name="section-9.2"></a><p></p>
<p class="First">Signs and Symptoms</p>
<p><span class="Bold Italics">Lopressor:</span> Potential signs and symptoms associated with overdosage with Lopressor are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>.</p>
<p><span class="Bold Italics">Hydrochlorothiazide:</span> The most prominent feature of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is acute loss of fluid and electrolytes.</p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
<p><span class="Bold Italics">Neuromuscular:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> of the calf muscles, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, impairment of consciousness.</p>
<p><span class="Bold Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>.</p>
<p><span class="Bold Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, or <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> (due to hemoconcentration).</p>
<p><span class="Bold Italics">Laboratory Findings:</span> <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span>; increased BUN (especially in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>).</p>
<p><span class="Bold Italics">Combined <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>:</span> Signs and symptoms may be aggravated or modified by concomitant intake of antihypertensive medication, barbiturates, curare, digitalis (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>), corticosteroids, narcotics, or alcohol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection22"></a><a name="section-9.3"></a><p></p>
<p class="First">Treatment</p>
<p>There is no specific antidote.</p>
<p>On the basis of the pharmacologic actions of Lopressor and hydrochlorothiazide, the following general measures should be employed:</p>
<p><span class="Bold Italics">Elimination of the Drug:</span> Inducement of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, gastric lavage, and activated charcoal.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>:</span> Atropine should be administered. If there is no response to vagal blockade, isoproterenol should be administered cautiously.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span> The patient's legs should be elevated and lost fluid and electrolytes (potassium, sodium) should be replaced. A vasopressor should be administered, e.g., levarterenol or dopamine.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>:</span> A beta<span class="Sub">2</span>-stimulating agent and/or a theophylline derivative should be administered.</p>
<p><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>:</span> A digitalis glycoside and diuretic should be administered. In <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> resulting from inadequate cardiac contractility, administration of dobutamine, isoproterenol, or glucagon may be considered.</p>
<p><span class="Bold Italics">Surveillance:</span> Fluid and electrolyte balance (especially serum potassium) and renal function should be monitored until conditions become normal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-10"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Dosage should be determined by individual titration (see <a href="#splSectionIndicationsUsage">INDICATIONS AND USAGE</a>).</p>
<p>Hydrochlorothiazide is usually given at a dosage of 12.5 to 50 mg per day. The usual initial dosage of Lopressor is 100 mg daily in single or divided doses. Dosage may be increased gradually until optimum blood pressure control is achieved. The effective dosage range is 100 to 450 mg per day. While once-daily dosing is effective and can maintain a reduction in blood pressure throughout the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period, and larger or more frequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day. Beta<span class="Sub">1</span> selectivity diminishes as dosage of Lopressor is increased.</p>
<p>The following dosage schedule may be used to administer from 100 to 200 mg of Lopressor per day and from 25 to 50 mg of hydrochlorothiazide per day:</p>
<table width="80%">
<col align="left" width="40%">
<col align="left" width="60%">
<tbody class="Headless">
<tr class="Botrule First">
<td align="left"><span class="Bold Italics">Lopressor HCT</span></td>
<td align="left"><span class="Bold Italics">Dosage</span></td>
</tr>
<tr>
<td align="left">
Tablets of 50/25
</td>
<td align="left">
2 tablets per day in single or divided doses
</td>
</tr>
<tr>
<td align="left">
Tablets of 100/25
</td>
<td align="left">
1 to 2 tablets per day in single or divided doses
</td>
</tr>
<tr class="Last">
<td align="left">
Tablets of 100/50
</td>
<td align="left">
1 tablet per day in single or divided doses
</td>
</tr>
</tbody>
</table>
<p>Dosing regimens that exceed 50 mg of hydrochlorothiazide per day are not recommended. When necessary, another antihypertensive agent may be added gradually, beginning with 50% of the usual recommended starting dose to avoid an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-11"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">Tablets 50/25 - capsule-shaped, white and mottled-blue, scored (imprinted Geigy on one side and 35 twice on the scored side), 50 mg of metoprolol tartrate and 25 mg of hydrochlorothiazide<br>    Bottles of 100..........................................NDC 30698-460-01</p>
<p>Tablets 100/25 - capsule-shaped, white and mottled-pink, scored (imprinted Geigy on one side and 53 twice on the scored side), 100 mg of metoprolol tartrate and 25 mg of hydrochlorothiazide<br>    Bottles of 100..........................................NDC 30698-461-01</p>
<p>Tablets 100/50 - capsule- shaped, white and mottled-yellow, scored (imprinted Geigy on one side and 73 twice on the scored side), 100 mg of metoprolol tartrate and 50 mg of hydrochlorothiazide<br>    Bottles of 100..........................................NDC 30698-462-01</p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from moisture.</p>
<p>Dispense in tight, light-resistant container (USP).</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Validus Pharmaceuticals LLC at 1-866-9VALIDUS (1-866-982-5438) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span></p>
<p><br>Distributed by:<br>Validus Pharmaceuticals LLC<br>Parsippany, New Jersey 07054<br>info@validuspharma.com<br>www.validuspharma.com<br>1-866-9VALIDUS</p>
<p>© 2012 Validus Pharmaceuticals LLC</p>
<p>October 2012</p>
<p>463000-01</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50/25 mg Tablet</span></p>
<p><br>NDC 30698-460-01</p>
<p>Lopressor HCT<span class="Sup">®</span><br>metoprolol tartrate USP 50 mg<br>hydrochlorothiazide USP 25 mg</p>
<p>50/25 mg<br>100 Tablets</p>
<p>R<span class="Sub">x</span> Only</p>
<div class="Figure"><img alt="
lopressor-hct-03
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d8964894-3cd8-41c1-a844-148d2ef38a88&amp;name=lopressor-hct-03.jpg"></div>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOPRESSOR HCT 		
					</strong><br><span class="contentTableReg">metoprolol tartrate and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:30698-460</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METOPROLOL TARTRATE</strong> (METOPROLOL) </td>
<td class="formItem">METOPROLOL TARTRATE</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) , blue (mottled-blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Geigy;35;35</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:30698-460-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018303</td>
<td class="formItem">12/31/1984</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Validus Pharmaceuticals LLC
							(801194619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novartis Corporation</td>
<td class="formItem"></td>
<td class="formItem">013238480</td>
<td class="formItem">manufacture(30698-460)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d8964894-3cd8-41c1-a844-148d2ef38a88</div>
<div>Set id: d8964894-3cd8-41c1-a844-148d2ef38a88</div>
<div>Version: 1</div>
<div>Effective Time: 20121022</div>
</div>
</div> <div class="DistributorName">Validus Pharmaceuticals LLC</div></p>
</body></html>
